You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of novel research tools and a database for mapping human mitochondrial tRNA modifications by mass spectrometry

    SBC: Ribonova Inc.            Topic: R42

    Summary In this fast track Phase I II STTR project a novel mass spectrometry method and a matched reagent kit will be developed for mapping modified nucleotides in human mitochondrial transfer RNA mt tRNA including the most abundant modification pseudouridine which hitherto has proved to be a technical challenge because it is an isomer of uridine These new research tools will be harnessed to build ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. BlueBox- a complete code blue data recorder

    SBC: NeoVative, Inc.            Topic: 400

    DESCRIPTION provided by applicant andquot Code blue andquot the term used in hospitals to call for an immediate cardiopulmonary resuscitation CPR signals dire emergencies where medical errors can occur and lives can be lost Reviewing CPR performance of the code blue team is a cornerstone for improving outcomes Thorough and accurate recording of code blue events enable detailed reviews to ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Developing efficient and safe cell-permeable reprogramming peptides for generation of iPS cells.

    SBC: Vivoscript, Inc.            Topic: 200

    DESCRIPTION provided by applicant The groundbreaking discovery of induced pluripotent stem cells iPSCs has opened a new page for developing personalized cell based therapies against various devastating human diseases without ethical concerns of using human embryonic stem cells However the future clinical applications of iPSCs remain in doubt due to potential risks of undesired genomic alter ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Developing a Diagnostic Blood Test for Sarcoidosis

    SBC: Sarcoidosis Diagnostic Testing LLC            Topic: NHLBI

    DESCRIPTION provided by applicant SARCOIDOSIS DIAGNOSTIC TESTING LLC is a medical diagnostics company developing a diagnostic blood test for sarcoidosis Sarcoidosis is a multisystem granulomatous disorder that affects per people per year in the U S and disproportionately affects African Americans and women Sarcoidosis can lead to advanced pulmonary fibrosis pulmonary hyperte ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Asthmagram: objective assessment of asthma symptoms in children

    SBC: NeoVative, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant Asthma is the most common chronic illness of childhood but many children have poorly controlled symptoms causing morbidities hospitalizations and costs The first step toward good asthma control is accurate assessment of symptoms Recall of the frequency and severity of symptoms is the cornerstone of asthma assessment Unfortunately recall by parents or ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. A Protective Tetravalent Vaccine Candidate for Dengue Fever Virus

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION provided by applicant There are approximately million cases of dengue fever each year with billion people at risk mostly in low income countries There are four serotypes of dengue fever virus DENV and in its uncomplicated form the disease is worthy of its indigenous name andquot break bone feverandquot An individual may suffer sequential infections with multiple DE ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD

    SBC: VIROGENICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms

    SBC: NeuroSigma, Inc.            Topic: 101

    DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Urocortin Gene Transfer for CHF a Paracrine Approach Using Intravenous AAV

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain safely and easily sufficient cardiac transgene expression Current methods of gene transfer for heart disease include intramuscular injection into heart muscle or intracoronary delivery approaches that are cumbersome to apply Consequently we have considered the u ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. SMALL MOLECULE ANTAGONISTS OF PF FOR THE TREATMENT AND PREVENTION OF HIT

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NHLBI

    DESCRIPTION provided by applicant We have discovered the first ever inhibitors of PF a platelet protein central to the pathophysiology of heparin induced thrombocytopenia HIT Heparin is a naturally occurring anticoagulant that prevents the formation of clots and extension of existing clots within the vasculature and major medical applications of heparin include dialysis cardiac catheteri ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government